DelveInsight's "TAGRISSO Market Size, Forecast, and Market Insight Report" highlights the details around TAGRISSO, a kinase ...

Operator Welcome to BioNTech's fourth quarter and full year 2024 earnings call. I would like to hand the call over to Michael ...

Q4 2024 Earnings Call Transcript March 10, 2025 Operator: Welcome to BioNTech’s Fourth Quarter and Full-Year 2024 Earnings ...

We have started exploring combinations of BNT327 with four ADCs directed against TROP2, HER2, HER3, B7H3 from our partnerships with Duality and MediLink and informed by a robust database of single ...

TAGRISSO has become a standard treatment due to its strong efficacy in both first-line and adjuvant settings. The growing prevalence of EGFR mutations, a rise in lung cancer diagnoses, and broader ...

The full audited consolidated financial statements as of and for the year ended December 31, 2024, can be found in BioNTech’s Annual Report on Form 20-F filed today with the United States Securities ...

The results suggest that AZ and Daiichi Sankyo could be in line for a second big win for a cancer ADC to follow Enhertu (trastuzumab deruxtecan), their HER2-directed drug which has just claimed a ...

Enhertu is approved for HER2-positive breast and gastric cancers ... The third – patritumab deruxtecan (HER3-DXd) – is a HER3-targeted ADC in late-stage clinical testing for lung cancer.

Objectives HER3 is a receptor tyrosine kinase that forms heterodimers with HER2 and EGFR and plays an important role in the pro-oncogenic signaling pathways of HER2+ breast cancer. We developed an ...

The pop star shares sons RZA, 2, and Riot, 19 months, with her partner A$AP Rocky Charlotte Phillipp is a Weekend Writer-Reporter at PEOPLE. She has been working at ...